Dual targeting of the insulin-like growth factor and collateral pathways in cancer: Combating drug resistance

Cancers

Volumn 3, Issue 3, 2011, Pages 3029-3054

  Ludwig, Joseph A ^a   Lamhamedi Cherradi, Salah Eddine ^a   Lee, Ho Young ^a   Naing, Aung ^a   Benjamin, Robert ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Combination therapy; Drug resistance; Ewing sarcoma; IGF 1R; Insulin like growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; FIGITUMUMAB; GEFITINIB; GEMCITABINE; GSK 1838705A; IMATINIB; INSULIN RECEPTOR; LIGAND; LINSITINIB; MEDI 573; MONOCLONAL ANTIBODY; NVP AEW 541; PEMETREXED; PERTUZUMAB; R 1507; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN C RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER; DRUG MECHANISM; DRUG TARGETING; DRUG WITHDRAWAL; EWING SARCOMA; HUMAN; LIGAND BINDING; LUNG CANCER; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OSTEOSARCOMA; PANCREAS CANCER; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; RECURRENT CANCER; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 80053203958     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers3033029     Document Type: Article

References (157)

1. Salmon, W.D., Jr.; Daughaday, W.H. A hormonally controlled serum factor which stimulatessulfate incorporation by cartilage in vitro. J. Lab. Clin. Med. 1957, 49, 825-836.
2. Atzori, F.; Traina, T.A.; Ionta, M.T.; Massidda, B. Targeting insulin-like growth factor type 1 receptor in cancer therapy. Target Oncol. 2009, 4, 255-266.
3. Bahr, C.; Groner, B. The insulin like growth factor-1 receptor (IGF-1R) as a drug target: Novel approaches to cancer therapy. Growth Horm. IGF Res. 2004, 14, 287-295.
4. Bahr, C.; Groner, B. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 2005, 23, 1-14.
5. Camidge, D.R.; Dziadziuszko, R.; Hirsch, F.R. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. Clin. Lung Cancer 2009, 10, 262-272.
6. Maki, R.G. Small is beautiful: Insulin-like growth factors and their role in growth, development, and cancer. J. Clin. Oncol. 2010, 28, 4985-4995.
7. Rosenzweig, S.A.; Atreya, H.S. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem. Pharmacol. 2010, 80, 1115-1124.
8. Moller, D.E.; Yokota, A.; Caro, J.F.; Flier, J.S. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol. Endocrinol. 1989, 3, 1263-1269.
9. Ullrich, A.; Gray, A.; Tam, A.W.; Yang-Feng, T.; Tsubokawa, M.; Collins, C.; Henzel, W.; Le Bon, T.; Kathuria, S.; Chen, E. et al. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986, 5, 2503-2512.
10. Scotlandi, K.; Benini, S.; Sarti, M.; Serra, M.; Lollini, P.L.; Maurici, D.; Picci, P.; Manara, M.C.; Baldini, N. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: A possible therapeutic target. Cancer Res. 1996, 56, 4570-4574.
11. Baserga, R. Targeting the IGF-1 receptor: From rags to riches. Eur. J. Cancer 2004, 40, 2013-2015.
12. Hubbard, S.R.; Wei, L.; Ellis, L.; Hendrickson, W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994, 372, 746-754.
13. Favelyukis, S.; Till, J.H.; Hubbard, S.R.; Miller, W.T. Structure and autoregulation of the insulinlike growth factor 1 receptor kinase. Nat. Struct. Biol. 2001, 8, 1058-1063.
14. Pautsch, A.; Zoephel, A.; Ahorn, H.; Spevak, W.; Hauptmann, R.; Nar, H. Crystal structure of bisphosphorylated IGF-1 receptor kinase: Insight into domain movements upon kinase activation. Structure 2001, 9, 955-965.
15. Kaushansky, A.; Gordus, A.; Chang, B.; Rush, J.; MacBeath, G. A quantitative study of the recruitment potential of all intracellular tyrosine residues on EGFR, FGFR1 and IGF1R. Mol. Biosyst. 2008, 4, 643-653.
16. Heldin, C.H. Dimerization of cell surface receptors in signal transduction. Cell 1995, 80, 213-223.
17. Baserga, R.; Peruzzi, F.; Reiss, K. The IGF-1 receptor in cancer biology. Int. J. Cancer 2003, 107, 873-877.
18. De Meyts, P.; Palsgaard, J.; Sajid, W.; Theede, A.M.; Aladdin, H. Structural biology of insulin and IGF-1 receptors. Novartis Found. Symp. 2004, 262, 160-171.
19. Nakae, J.; Kido, Y.; Accili, D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr. Rev. 2001, 22, 818-835.
20. Pollak, M. Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer. 2008, 8, 915-928.
21. Almeida, A.; Muleris, M.; Dutrillaux, B.; Malfoy, B. The insulin-like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer. Genes Chromosomes Cancer 1994, 11, 63-65.
22. Tarn, C.; Rink, L.; Merkel, E.; Flieder, D.; Pathak, H.; Koumbi, D.; Testa, J.R.; Eisenberg, B.; von Mehren, M.; Godwin, A.K. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc. Natl. Acad. Sci. USA 2008, 105, 8387-8392.
23. Armengol, G.; Knuutila, S.; Lluis, F.; Capella, G.; Miro, R.; Caballin, M.R. DNA copy number changes and evaluation of MYC, IGF1R, and FES amplification in xenografts of pancreatic adenocarcinoma. Cancer Genet. Cytogenet. 2000, 116, 133-141.
24. Natrajan, R.; Reis-Filho, J.S.; Little, S.E.; Messahel, B.; Brundler, M.A.; Dome, J.S.; Grundy, P.E.; Vujanic, G.M.; Pritchard-Jones, K.; Jones, C. Blastemal expression of type I insulin-like growth factor receptor in Wilms' tumors is driven by increased copy number and correlates with relapse. Cancer Res. 2006, 66, 11148-11155.
25. Nair, P.N.; De Armond, D.T.; Adamo, M.L.; Strodel, W.E.; Freeman, J.W. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2. Oncogene 2001, 20, 8203-8214.
26. Benini, S.; Manara, M.C.; Cerisano, V.; Perdichizzi, S.; Strammiello, R.; Serra, M.; Picci, P.; Scotlandi, K. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int. J. Cancer 2004, 108, 358-366.
27. Tao, Y.; Pinzi, V.; Bourhis, J.; Deutsch, E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer. Nat. Clin. Pract. Oncol. 2007, 4, 591-602.
28. Wan, X.; Helman, L.J. The biology behind mTOR inhibition in sarcoma. Oncologist 2007, 12, 1007-1018.
29. Fasolo, A.; Sessa, C. mTOR inhibitors in the treatment of cancer. Expert. Opin. Investig. Drugs 2008, 17, 1717-1734.
30. Chang, Q.; Li, Y.; White, M.F.; Fletcher, J.A.; Xiao, S. Constitutive activation of insulin receptor substrate 1 is a frequent event in human tumors: Therapeutic implications. Cancer Res. 2002, 62, 6035-6038.
31. Alberobello, A.T.; D'Esposito, V.; Marasco, D.; Doti, N.; Ruvo, M.; Bianco, R.; Tortora, G.; Esposito, I.; Fiory, F.; Miele, C.; Beguinot, F.; Formisano, P. Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. J. Biol. Chem. 2010, 285, 6563-6572.
32. Hirschfeld, S.; Helman, L. Diverse roles of insulin-like growth factors in pediatric solid tumors. In Vivo 1994, 8, 81-90.
33. Kim, S.Y.; Wan, X.; Helman, L.J. Targeting IGF-1R in the treatment of sarcomas: Past, present and future. Bull. Cancer 2009, 96, E52-60.
34. Dricu, A.; Kanter, L.; Wang, M.; Nilsson, G.; Hjertman, M.; Wejde, J.; Larsson, O. Expression of the insulin-like growth factor 1 receptor (IGF-1R) in breast cancer cells: evidence for a regulatory role of dolichyl phosphate in the transition from an intracellular to an extracellular IGF-1 pathway. Glycobiology 1999, 9, 571-579.
35. Yu, H.; Berkel, H. Insulin-like growth factors and cancer. J. La. State. Med. Soc. 1999, 151, 218-223.
36. Moore, M.G.; Wetterau, L.A.; Francis, M.J.; Peehl, D.M.; Cohen, P. Novel stimulatory role for insulin-like growth factor binding protein-2 in prostate cancer cells. Int. J. Cancer. 2003, 105, 14-19.
37. Ma, Z.; Dong, A.; Kong, M.; Qian, J. Silencing of the type 1 insulin-like growth factor receptor increases the sensitivity to apoptosis and inhibits invasion in human lung adenocarcinoma A549 cells. Cell Mol. Biol. Lett. 2007, 12, 556-572.
38. Shevah, O.; Laron, Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm. IGF Res. 2007, 17, 54-57.
39. Steuerman, R.; Shevah, O.; Laron, Z. Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. Eur. J. Endocrinol. 2011, 164, 485-489.
40. Li, R.; Pourpak, A.; Morris, S.W. Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J. Med. Chem. 2009, 52, 4981-5004.
41. Frasca, F.; Pandini, G.; Vigneri, R.; Goldfine, I.D. Insulin and hybrid insulin/IGF receptors are major regulators of breast cancer cells. Breast Dis. 2003, 17, 73-89.
42. Vaira, V.; Lee, C.W.; Goel, H.L.; Bosari, S.; Languino, L.R.; Altieri, D.C. Regulation of surviving expression by IGF-1/mTOR signaling. Oncogene 2007, 26, 2678-2684.
43. Jones, H.E.; Goddard, L.; Gee, J.M.; Hiscox, S.; Rubini, M.; Barrow, D.; Knowlden, J.M.; Williams, S.; Wakeling, A.E.; Nicholson, R.I. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr. Relat. Cancer 2004, 11, 793-814.
44. Lu, Y.; Zi, X.; Zhao, Y.; Mascarenhas, D.; Pollak, M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J. Natl. Cancer Inst. 2001, 93, 1852-1857.
45. Nahta, R.; Yuan, L.X.; Zhang, B.; Kobayashi, R.; Esteva, F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005, 65, 11118-11128.
46. Chakraborty, A.K.; Liang, K.; DiGiovanna, M.P. Co-targeting insulin-like growth factor I receptor and HER2: Dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res. 2008, 68, 1538-1545.
47. Browne, B.C.; Crown, J.; Venkatesan, N.; Duffy, M.J.; Clynes, M.; Slamon, D.; O'Donovan, N. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann. Oncol. 2011, 22, 68-73.
48. van der Veeken, J.; Oliveira, S.; Schiffelers, R.M.; Storm, G.; van Bergen En Henegouwen, P.M.; Roovers, R.C. Crosstalk between epidermal growth factor receptor-and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr. Cancer Drug Targets 2009, 9, 748-760.
49. Roznovanu, S.L.; Amalinci, C.; Radulescu, D. Molecular mechanisms in hormone-resistant prostate cancer. Rev. Med. Chir. Soc. Med. Nat. Iasi. 2005, 109, 577-583.
50. Wu, J.D.; Odman, A.; Higgins, L.M.; Haugk, K.; Vessella, R.; Ludwig, D.L.; Plymate, S.R. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgendependent and androgen-independent xenograft human prostate tumors. Clin. Cancer Res. 2005, 11, 3065-3074.
51. Kimura, K.; Markowski, M.; Bowen, C.; Gelmann, E.P. Androgen blocks apoptosis of hormonedependent prostate cancer cells. Cancer Res. 2001, 61, 5611-5618.
52. Morgillo, F.; Woo, J.K.; Kim, E.S.; Hong, W.K.; Lee, H.Y. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 2006, 66, 10100-10111.
53. Goetsch, L.; Gonzalez, A.; Leger, O.; Beck, A.; Pauwels, P.J.; Haeuw, J.F.; Corvaia, N. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int. J. Cancer 2005, 113, 316-328.
54. Gong, Y.; Yao, E.; Shen, R.; Goel, A.; Arcila, M.; Teruya-Feldstein, J.; Zakowski, M.F.; Frankel, S.; Peifer, M.; Thomas, R.K.; Ladanyi, M.; Pao, W. High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One 2009, 4, e7273.
55. Lu, D.; Zhang, H.; Koo, H.; Tonra, J.; Balderes, P.; Prewett, M.; Corcoran, E.; Mangalampalli, V.; Bassi, R.; Anselma, D.; Patel, D.; Kang, X.; Ludwig, D.L.; Hicklin, D.J.; Bohlen, P.; Witte, L.; Zhu, Z. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J. Biol. Chem. 2005, 280, 19665-19672.
56. Bardelli, A.; Siena, S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 2010, 28, 1254-1261.
57. Takahari, D.; Yamada, Y.; Okita, N.T.; Honda, T.; Hirashima, Y.; Matsubara, J.; Takashima, A.; Kato, K.; Hamaguchi, T.; Shirao, K.; Shimada, Y.; Shimoda, T. Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. Oncology 2009, 76, 42-48.
58. Hopfner, M.; Sutter, A.P.; Huether, A.; Baradari, V.; Scherubl, H. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J. Gastroenterol. 2006, 12, 5635-5643.
59. Donovan, E.A.; Kummar, S. Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit. Rev. Oncol. Hematol. 2008, 66, 91-98.
60. Ma, J.; Pollak, M.N.; Giovannucci, E.; Chan, J.M.; Tao, Y.; Hennekens, C.H.; Stampfer, M.J. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J. Natl. Cancer Inst. 1999, 91, 620-625.
61. Ma, J.; Stampfer, M.; Pollak, M. RESPONSE: More about: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF- binding protein-3. J. Natl. Cancer Inst. 2000, 92, 1949.
62. Reidy, D.L.; Vakiani, E.; Fakih, M.G.; Saif, M.W.; Hecht, J.R.; Goodman-Davis, N.; Hollywood, E.; Shia, J.; Schwartz, J.; Chandrawansa, K.; Dontabhaktuni, A.; Youssoufian, H.; Solit, D.B.; Saltz, L.B. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J. Clin. Oncol. 2010, 28, 4240-4246.
63. Hellawell, G.O.; Turner, G.D.; Davies, D.R.; Poulsom, R.; Brewster, S.F.; Macaulay, V.M. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res. 2002, 62, 2942-2950.
64. Hakam, A.; Fang, Q.; Karl, R.; Coppola, D. Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig. Dis. Sci. 2003, 48, 1972-1978.
65. Freeman, J.W.; Mattingly, C.A.; Strodel, W.E. Increased tumorigenicity in the human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-beta type RII receptor. J. Cell. Physiol. 1995, 165, 155-163.
66. Bao, B.; Wang, Z.; Li, Y.; Kong, D.; Ali, S.; Banerjee, S.; Ahmad, A.; Sarkar, F.H. The complexities of obesity and diabetes with the development and progression of pancreatic cancer. Biochim. Biophys. Acta 2011, 1815, 135-146.
67. Tomizawa, M.; Shinozaki, F.; Sugiyama, T.; Yamamoto, S.; Sueishi, M.; Yoshida, T. Insulin-like growth factor-I receptor in proliferation and motility of pancreatic cancer. World. J. Gastroenterol. 2010, 16, 1854-1858.
68. Bergmann, U.; Funatomi, H.; Yokoyama, M.; Beger, H.G.; Korc, M. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res. 1995, 55, 2007-2011.
69. Stoeltzing, O.; Liu, W.; Reinmuth, N.; Fan, F.; Parikh, A.A.; Bucana, C.D.; Evans, D.B.; Semenza, G.L.; Ellis, L.M. Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am. J. Pathol. 2003, 163, 1001-1011.
70. Maloney, E.K.; McLaughlin, J.L.; Dagdigian, N.E.; Garrett, L.M.; Connors, K.M.; Zhou, X.M.; Blattler, W.A.; Chittenden, T.; Singh, R. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res. 2003, 63, 5073-5083.
71. Kim, W.Y.; Jin, Q.; Oh, S.H.; Kim, E.S.; Yang, Y.J.; Lee, D.H.; Feng, L.; Behrens, C.; Prudkin, L.; Miller, Y.E.; Lee, J.J.; Lippman, S.M.; Hong, W.K.; Wistuba, II; Lee, H.Y. Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development. Cancer Res. 2009, 69, 7439-7448.
72. Dziadziuszko, R.; Camidge, D.R.; Hirsch, F.R. The insulin-like growth factor pathway in lung cancer. J. Thorac. Oncol. 2008, 3, 815-818.
73. Yu, H.; Spitz, M.R.; Mistry, J.; Gu, J.; Hong, W.K.; Wu, X. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J. Natl. Cancer Inst. 1999, 91, 151-156.
74. London, S.J.; Yuan, J.M.; Travlos, G.S.; Gao, Y.T.; Wilson, R.E.; Ross, R.K.; Yu, M.C. Insulinlike growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J. Natl. Cancer Inst. 2002, 94, 749-754.
75. Renehan, A.G.; Zwahlen, M.; Minder, C.; O'Dwyer, S.T.; Shalet, S.M.; Egger, M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: Systematic review and metaregression analysis. Lancet 2004, 363, 1346-1353.
76. Gualberto, A.; Karp, D.D. Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin. Lung Cancer 2009, 10, 273-280.
77. Karp, D.D.; Paz-Ares, L.G.; Novello, S.; Haluska, P.; Garland, L.; Cardenal, F.; Blakely, L.J.; Eisenberg, P.D.; Langer, C.J.; Blumenschein, G., Jr.; Johnson, F.M.; Green, S.; Gualberto, A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2009, 27, 2516-2522.
78. Méndez, M.; Custodio, A.; Provencio, M. New molecular targeted therapies for advanced nonsmall-cell lung cancer. J. Thoracic Dis. 2011, 3, 30-56.
79. Gualberto, A.; Dolled-Filhart, M.; Gustavson, M.; Christiansen, J.J.; Wang, Y.F.; Hixon, M.L.; Reynolds, J.M.; McDonald, S.; Ang, A.; Rimm, D.L.; Langer, C.; Blakely, J.; Garland, L.L.; Paz-Ares, L.; Karp, D.D.; Lee, A.V. Molecular Analysis of Non-Small Cell Lung Cancer (NSCLC) Identifies Subsets with Different Sensitivity to Insulin like Growth Factor I Receptor (IGF-IR) Inhibition. Clin. Cancer Res. 2010, 16, 4654-4665.
80. Toretsky, J.A.; Kalebic, T.; Blakesley, V.; LeRoith, D.; Helman, L.J. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J. Biol. Chem. 1997, 272, 30822-30827.
81. Cironi, L.; Riggi, N.; Provero, P.; Wolf, N.; Suva, M.L.; Suva, D.; Kindler, V.; Stamenkovic, I. IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells. PLoS. ONE 2008, 3, e2634.
82. Prieur, A.; Tirode, F.; Cohen, P.; Delattre, O. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol. Cell Biol. 2004, 24, 7275-7283.
83. Toretsky, J.A.; Steinberg, S.M.; Thakar, M.; Counts, D.; Pironis, B.; Parente, C.; Eskenazi, A.; Helman, L.; Wexler, L.H. Insulin-like growth factor type 1 (IGF-1) and IGF binding protein-3 in patients with Ewing sarcoma family of tumors. Cancer 2001, 92, 2941-2947.
84. Windsor, R.; Strauss, S.; Seddon, B.; Whelan, J. Experimental therapies in Ewing's sarcoma. Expert. Opin. Investig. Drugs 2009, 18, 143-159.
85. Yuen, J.S.; Macaulay, V.M. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert. Opin. Ther. Targets 2008, 12, 589-603.
86. Janeway, K.A.; Zhu, M.J.; Barretina, J.; Perez-Atayde, A.; Demetri, G.D.; Fletcher, J.A. Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification. Int. J. Cancer 2010, 127, 2718-2722.
87. Pandini, G.; Wurch, T.; Akla, B.; Corvaia, N.; Belfiore, A.; Goetsch, L. Functional responses and in vivo anti-tumour activity of h7C10: a humanised monoclonal antibody with neutralizing activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur. J. Cancer 2007, 43, 1318-1327.
88. Buck, E.; Mulvihill, M. Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert. Opin. Investig. Drugs 2011, 20, 605-621.
89. Hixon, M.L.; Paccagnella, L.; Millham, R.; Perez-Olle, R.; Gualberto, A. Development of inhibitors of the IGF-IR/PI3K/Akt/mTOR pathway. Rev. Recent Clin. Trials 2010, 5, 189-208.
90. Hartog, H.; Wesseling, J.; Boezen, H.M.; van der Graaf, W.T. The insulin-like growth factor 1 receptor in cancer: Old focus, new future. Eur. J. Cancer 2007, 43, 1895-1904.
91. Olmos, D.; Martins, A.S.; Jones, R.L.; Alam, S.; Scurr, M.; Judson, I.R. Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations. Sarcoma 2011, 2011, 402508.
92. Wolpin, B.M.; Meyerhardt, J.A.; Chan, A.T.; Ng, K.; Chan, J.A.; Wu, K.; Pollak, M.N.; Giovannucci, E.L.; Fuchs, C.S. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J. Clin. Oncol. 2009, 27, 176-185.
93. Merchant, M.S.; Woo, C.W.; Mackall, C.L.; Thiele, C.J. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity. J. Natl. Cancer Inst. 2002, 94, 1673-1679.
94. Scotlandi, K.; Manara, M.C.; Hattinger, C.M.; Benini, S.; Perdichizzi, S.; Pasello, M.; Bacci, G.; Zanella, L.; Bertoni, F.; Picci, P.; Serra, M. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur. J. Cancer 2005, 41, 1349-1361.
95. Martins, A.S.; Ordonez, J.L.; Garcia-Sanchez, A.; Herrero, D.; Sevillano, V.; Osuna, D.; Mackintosh, C.; Caballero, G.; Otero, A.P.; Poremba, C.; Madoz-Gurpide, J.; de Alava, E. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res. 2008, 68, 6260-6270.
96. Bond, M.; Bernstein, M.L.; Pappo, A.; Schultz, K.R.; Krailo, M.; Blaney, S.M.; Adamson, P.C. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study. Pediatr. Blood Cancer 2008, 50, 254-258.
97. Timeus, F.; Crescenzio, N.; Fandi, A.; Doria, A.; Foglia, L.; Cordero di Montezemolo, L. In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines. Oncol. Rep. 2008, 19, 353-359.
98. Martins, A.S.; Mackintosh, C.; Martin, D.H.; Campos, M.; Hernandez, T.; Ordonez, J.L.; de Alava, E. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin. Cancer Res. 2006, 12, 3532-3540.
99. Andersson, M.K.; Aman, P. Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. Cancer Cell. Int. 2008, 8, 1.
100. Potratz, J.C.; Saunders, D.N.; Wai, D.H.; Ng, T.L.; McKinney, S.E.; Carboni, J.M.; Gottardis, M.M.; Triche, T.J.; Jurgens, H.; Pollak, M.N.; Aparicio, S.A.; Sorensen, P.H. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res. 2010, 70, 8770-8781.
101. Huang, F.; Greer, A.; Hurlburt, W.; Han, X.; Hafezi, R.; Wittenberg, G.M.; Reeves, K.; Chen, J.; Robinson, D.; Li, A.; Lee, F.Y.; Gottardis, M.M.; Clark, E.; Helman, L.; Attar, R.M.; Dongre, A.; Carboni, J.M. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 2009, 69, 161-170.
102. Girnita, L.; Girnita, A.; Larsson, O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. USA 2003, 100, 8247-8252.
103. Froment, P.; Dupont, J.; Christophe-Marine, J. Mdm2 exerts pro-apoptotic activities by antagonizing insulin-like growth factor-I-mediated survival. Cell Cycle 2008, 7, 3098-3103.
104. Kovar, H.; Auinger, A.; Jug, G.; Aryee, D.; Zoubek, A.; Salzer-Kuntschik, M.; Gadner, H. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene 1993, 8, 2683-2690.
105. Cao, L.; Yu, Y.; Darko, I.; Currier, D.; Mayeenuddin, L.H.; Wan, X.; Khanna, C.; Helman, L.J. Addiction to elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res. 2008, 68, 8039-8048.
106. Ludwig, J.A.; Weinstein, J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer 2005, 5, 845-856.
107. Garofalo, C.; Manara, M.C.; Nicoletti, G.; Marino, M.T.; Lollini, P.L.; Astolfi, A.; Pandini, G.; Lopez-Guerrero, J.A.; Schaefer, K.L.; Belfiore, A.; Picci, P.; Scotlandi, K. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011, 30, 2730-2740.
108. Kolb, E.A.; Gorlick, R.; Houghton, P.J.; Morton, C.L.; Lock, R.; Carol, H.; Reynolds, C.P.; Maris, J.M.; Keir, S.T.; Billups, C.A.; Smith, M.A. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 50, 1190-1197.
109. Mulvihill, M.J.; Cooke, A.; Rosenfeld-Franklin, M.; Buck, E.; Foreman, K.; Landfair, D.; O'Connor, M.; Pirritt, C.; Sun, Y.; Yao, Y.; Arnold, L.D.; Gibson, N.W.; Ji, Q.S. Discovery of OSI-906: A selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 2009, 1, 1153-1171.
110. McKinley, E.T.; Bugaj, J.E.; Zhao, P.; Guleryuz, S.; Mantis, C.; Gokhale, P.C.; Wild, R.; Manning, H.C. 18FDG-PET predicts pharmacodynamic response to OSI-906, a dual IGF-1R/IR inhibitor, in preclinical mouse models of lung cancer. Clin. Cancer Res. 2011, 17, 3332-3340.
111. Buck, E.; Gokhale, P.C.; Koujak, S.; Brown, E.; Eyzaguirre, A.; Tao, N.; Rosenfeld-Franklin, M.; Lerner, L.; Chiu, M.I.; Wild, R.; Epstein, D.; Pachter, J.A.; Miglarese, M.R. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol. Cancer Ther. 2010, 9, 2652-2664.
112. Dong, J.; Demarest, S.J.; Sereno, A.; Tamraz, S.; Langley, E.; Doern, A.; Snipas, T.; Perron, K.; Joseph, I.; Glaser, S.M.; Ho, S.N.; Reff, M.E.; Hariharan, K. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol. Cancer Ther. 2010, 9, 2593-2604.
113. Gao, J.; Chesebrough, J.W.; Cartlidge, S.A.; Ricketts, S.A.; Incognito, L.; Veldman-Jones, M.; Blakey, D.C.; Tabrizi, M.; Jallal, B.; Trail, P.A.; Coats, S.; Bosslet, K.; Chang, Y.S. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res. 2011, 71, 1029-1040.
114. Camirand, A.; Pollak, M. Co-targeting IGF-1R and c-kit: Synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br. J. Cancer 2004, 90, 1825-1829.
115. Sabbatini, P.; Korenchuk, S.; Rowand, J.L.; Groy, A.; Liu, Q.; Leperi, D.; Atkins, C.; Dumble, M.; Yang, J.; Anderson, K.; Kruger, R.G.; Gontarek, R.R.; Maksimchuk, K.R.; Suravajjala, S.; Lapierre, R.R.; Shotwell, J.B.; Wilson, J.W.; Chamberlain, S.D.; Rabindran, S.K.; Kumar, R. GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol. Cancer Ther. 2009, 8, 2811-2820.
116. Quek, R.; Wang, Q.; Morgan, J.A.; Shapiro, G.I.; Butrynski, J.E.; Ramaiya, N.; Huftalen, T.; Jederlinic, N.; Manola, J.; Wagner, A.J.; Demetri, G.D.; George, S. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin. Cancer Res. 2011, 17, 871-879.
117. Beltran, P.J.; Chung, Y.A.; Moody, G.; Mitchell, P.; Cajulis, E.; Vonderfecht, S.; Kendall, R.; Radinsky, R.; Calzone, F.J. Efficacy of Ganitumab (AMG 479), Alone and in Combination With Rapamycin, in Ewing's and Osteogenic Sarcoma Models. J. Pharmacol. Exp. Ther. 2011, 337, 644-654.
118. Dong, J.; Sereno, A.; Aivazian, D.; Langley, E.; Miller, B.; Snyder, W.; Chan, E.; Cantele, M.; Morena, R.; Joseph, I.; Boccia, A.; Virata, C.; Gamez, J.; Yco, G.; Favis, M.; Wu, X.; Graff, C.; Wang, Q.; Rohde, E.; Berquist, L.; Huang, F.; Zhang, Y.; Gao, S.; Ho, S.; Demarest, S.; Reff, M.; Hariharan, K.; Glaser, S. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011, 3, 272-288.
119. Nguyen, K.S.; Kobayashi, S.; Costa, D.B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin. Lung Cancer 2009, 10, 281-289.
120. Buck, E.; Eyzaguirre, A.; Rosenfeld-Franklin, M.; Thomson, S.; Mulvihill, M.; Barr, S.; Brown, E.; O'Connor, M.; Yao, Y.; Pachter, J.; Miglarese, M.; Epstein, D.; Iwata, K.K.; Haley, J.D.; Gibson, N.W.; Ji, Q.S. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res. 2008, 68, 8322-8332.
121. Guix, M.; Faber, A.C.; Wang, S.E.; Olivares, M.G.; Song, Y.; Qu, S.; Rinehart, C.; Seidel, B.; Yee, D.; Arteaga, C.L.; Engelman, J.A. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 2008, 118, 2609-2619.
122. Haluska, P.; Carboni, J.M.; TenEyck, C.; Attar, R.M.; Hou, X.; Yu, C.; Sagar, M.; Wong, T.W.; Gottardis, M.M.; Erlichman, C. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol. Cancer Ther. 2008, 7, 2589-2598.
123. Wheeler, D.L.; Huang, S.; Kruser, T.J.; Nechrebecki, M.M.; Armstrong, E.A.; Benavente, S.; Gondi, V.; Hsu, K.T.; Harari, P.M. Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members. Oncogene 2008, 27, 3944-3956.
124. Wu, J.D.; Haugk, K.; Woodke, L.; Nelson, P.; Coleman, I.; Plymate, S.R. Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J. Cell. Biochem. 2006, 99, 392-401.
125. Chong, K.; Subramanian, A.; Sharma, A.; Mokbel, K. Measuring IGF-1, ER-alpha and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer. Anticancer Res. 2011, 31, 23-32.
126. Chong, K.Y.; Subramanian, A.; Mokbel, K.; Sharma, A.K. The prognostic significance of the insulin-like growth factor-1 ligand and receptor expression in breast cancer tissue. J. Surg. Oncol. 2011, 10.1002/jso.21916.
127. Song, R.X.; Barnes, C.J.; Zhang, Z.; Bao, Y.; Kumar, R.; Santen, R.J. The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc. Natl. Acad. Sci. USA 2004, 101, 2076-2081.
128. Song, R.X.; McPherson, R.A.; Adam, L.; Bao, Y.; Shupnik, M.; Kumar, R.; Santen, R.J. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Mol. Endocrinol. 2002, 16, 116-127.
129. Song, R.X.; Santen, R.J.; Kumar, R.; Adam, L.; Jeng, M.H.; Masamura, S.; Yue, W. Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Mol. Cell. Endocrinol. 2002, 193, 29-42.
130. Wahner Hendrickson, A.E.; Haluska, P.; Schneider, P.A.; Loegering, D.A.; Peterson, K.L.; Attar, R.; Smith, B.D.; Erlichman, C.; Gottardis, M.; Karp, J.E.; Carboni, J.M.; Kaufmann, S.H. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: Effect of the dual-receptor inhibitor BMS-536924 in vitro. Cancer Res. 2009, 69, 7635-7643.
131. Papa, V.; Gliozzo, B.; Clark, G.M.; McGuire, W.L.; Moore, D.; Fujita-Yamaguchi, Y.; Vigneri, R.; Goldfine, I.D.; Pezzino, V. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 1993, 53, 3736-3740.
132. Milazzo, G.; Giorgino, F.; Damante, G.; Sung, C.; Stampfer, M.R.; Vigneri, R.; Goldfine, I.D.; Belfiore, A. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res. 1992, 52, 3924-3930.
133. Ulanet, D.B.; Ludwig, D.L.; Kahn, C.R.; Hanahan, D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc. Natl. Acad. Sci. USA 2010, 107, 10791-10798.
134. Jerome, L.; Alami, N.; Belanger, S.; Page, V.; Yu, Q.; Paterson, J.; Shiry, L.; Pegram, M.; Leyland-Jones, B. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res. 2006, 66, 7245-7252.
135. Alami, N.; Page, V.; Yu, Q.; Jerome, L.; Paterson, J.; Shiry, L.; Leyland-Jones, B. Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm. IGF Res. 2008, 18, 487-496.
136. Camirand, A.; Lu, Y.; Pollak, M. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med. Sci. Monit. 2002, 8, BR521-526.
137. Burtrum, D.; Zhu, Z.; Lu, D.; Anderson, D.M.; Prewett, M.; Pereira, D.S.; Bassi, R.; Abdullah, R.; Hooper, A.T.; Koo, H.; Jimenez, X.; Johnson, D.; Apblett, R.; Kussie, P.; Bohlen, P.; Witte, L.; Hicklin, D.J.; Ludwig, D.L. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res. 2003, 63, 8912-8921.
138. Tonra, J.R.; Deevi, D.S.; Corcoran, E.; Li, H.; Wang, S.; Carrick, F.E.; Hicklin, D.J. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin. Cancer Res. 2006, 12, 2197-2207.
139. Balana, M.E.; Labriola, L.; Salatino, M.; Movsichoff, F.; Peters, G.; Charreau, E.H.; Elizalde, P.V. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 2001, 20, 34-47.
140. Beltran, P.J.; Mitchell, P.; Chung, Y.A.; Cajulis, E.; Lu, J.; Belmontes, B.; Ho, J.; Tsai, M.M.; Zhu, M.; Vonderfecht, S.; Baserga, R.; Kendall, R.; Radinsky, R.; Calzone, F.J. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol. Cancer. Ther. 2009, 8, 1095-1105.
141. LeRoith, D.; Roberts, C.T., Jr. The insulin-like growth factor system and cancer. Cancer Lett. 2003, 195, 127-137.
142. Lang, S.A.; Moser, C.; Gaumann, A.; Klein, D.; Glockzin, G.; Popp, F.C.; Dahlke, M.H.; Piso, P.; Schlitt, H.J.; Geissler, E.K.; Stoeltzing, O. Targeting heat shock protein 90 in pancreatic cancer impairs insulin-like growth factor-I receptor signaling, disrupts an interleukin-6/signaltransducer and activator of transcription 3/hypoxia-inducible factor-1alpha autocrine loop, and reduces orthotopic tumor growth. Clin. Cancer Res. 2007, 13, 6459-6468.
143. Hewish, M.; Chau, I.; Cunningham, D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat. Anticancer Drug Discov. 2009, 4, 54-72.
144. Heidegger, I.; Pircher, A.; Klocker, H.; Massoner, P. Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol. Ther. 2011, 11, 701-707.
145. Haruta, T.; Uno, T.; Kawahara, J.; Takano, A.; Egawa, K.; Sharma, P.M.; Olefsky, J.M.; Kobayashi, M. A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol. Endocrinol. 2000, 14, 783-794.
146. Liu, T.J.; LaFortune, T.; Honda, T.; Ohmori, O.; Hatakeyama, S.; Meyer, T.; Jackson, D.; de Groot, J.; Yung, W.K. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo. Mol. Cancer Ther. 2007, 6, 1357-1367.
147. Liu, W.; Bloom, D.A.; Cance, W.G.; Kurenova, E.V.; Golubovskaya, V.M.; Hochwald, S.N. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008, 29, 1096-1107.
148. Zheng, D.; Golubovskaya, V.; Kurenova, E.; Wood, C.; Massoll, N.A.; Ostrov, D.; Cance, W.G.; Hochwald, S.N. A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. Mol. Carcinog. 2010, 49, 200-209.
149. Zheng, D.; Kurenova, E.; Ucar, D.; Golubovskaya, V.; Magis, A.; Ostrov, D.; Cance, W.G.; Hochwald, S.N. Targeting of the protein interaction site between FAK and IGF-1R. Biochem. Biophys. Res. Commun. 2009, 388, 301-305.
150. Bonneterre, J.; Peyrat, J.P.; Beuscart, R.; Demaille, A. Prognostic significance of insulin-like growth factor 1 receptors in human breast cancer. Cancer Res. 1990, 50, 6931-6935.
151. Nielsen, T.O.; Andrews, H.N.; Cheang, M.; Kucab, J.E.; Hsu, F.D.; Ragaz, J.; Gilks, C.B.; Makretsov, N.; Bajdik, C.D.; Brookes, C.; Neckers, L.M.; Evdokimova, V.; Huntsman, D.G.; Dunn, S.E. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. Cancer Res. 2004, 64, 286-291.
152. Agrawal, A.; Gutteridge, E.; Gee, J.M.; Nicholson, R.I.; Robertson, J.F. Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr. Relat. Cancer 2005, 12 (Suppl. 1), S135-S144.
153. Jin, Q.; Esteva, F.J. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13, 485-498.
154. Jones, H.E.; Gee, J.M.; Barrow, D.; Tonge, D.; Holloway, B.; Nicholson, R.I. Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. Br. J. Cancer 2006, 95, 172-180.
155. Kurmasheva, R.T.; Huang, S.; Houghton, P.J. Predicted mechanisms of resistance to mTOR inhibitors. Br. J. Cancer 2006, 95, 955-960.
156. Wan, X.; Harkavy, B.; Shen, N.; Grohar, P.; Helman, L.J. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26, 1932-1940.
157. Masiello, D.; Mohi, M.G.; McKnight, N.C.; Smith, B.; Neel, B.G.; Balk, S.P.; Bubley, G.J. Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer. Cancer Biol. Ther. 2007, 6, 195-201.